GSK plc (NYSE:GSK) Shares Sold by Signet Financial Management LLC

Signet Financial Management LLC cut its holdings in GSK plc (NYSE:GSK) by 12.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 9,412 shares of the pharmaceutical company’s stock after selling 1,334 shares during the period. Signet Financial Management LLC’s holdings in GSK were worth $318,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. FMR LLC increased its stake in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of GSK by 13.9% during the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after acquiring an additional 1,773,020 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of GSK during the 2nd quarter worth about $52,487,000. Fisher Asset Management LLC boosted its position in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its holdings in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on GSK shares. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

NYSE:GSK opened at $32.71 on Tuesday. GSK plc has a twelve month low of $32.55 and a twelve month high of $45.92. The firm has a market capitalization of $67.79 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 1.52 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm’s fifty day simple moving average is $34.30 and its 200 day simple moving average is $38.12.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.80%. GSK’s dividend payout ratio is presently 95.45%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.